

IN THE CLAIMS:

Claims 1-62 (canceled)

63 (new): A method of treating a mammal having Sjögren's syndrome, the method comprising administering to the mammal a composition comprising soluble BAFF-R in an amount and for a period of time sufficient to reduce immunoglobulin production in the mammal.

64 (new): The method of claim 63, wherein the mammal is a human.

65 (new): The method of claim 63, wherein the mammal is a mouse.

66 (new): The method of claim 65, wherein the mouse is a BAFF Tg mouse.

67 (new): The method of claim 63, wherein the salivary gland of the mammal is infiltrated by MZ-like B cells.

68 (new): The method of claim 63, wherein BAFF-R is human.

69 (new): The method of claim 68, wherein the soluble BAFF-R comprises a portion of SEQ ID NO:27 that binds to BAFF.

70 (new): The method of claim 63, wherein BAFF-R is murine.

71 (new): The method of claim 70, wherein the soluble BAFF-R comprises a portion of SEQ ID NO:28 that binds to BAFF.

72 (new): The method of claim 63, wherein the soluble BAFF-R comprises an immunoglobulin Fc domain.

73 (new): The method of claim 72, wherein the immunoglobulin Fc domain is a human immunoglobulin Fc domain.

74 (new): A method of treating a mammal having Sjögren's syndrome, the method comprising administering to the mammal a composition comprising soluble BAFF-R in an amount and for a period of time sufficient to reduce B cell growth in the mammal.

75 (new): The method of claim 74, wherein the mammal is a human.

76 (new): The method of claim 74, wherein the mammal is a mouse.

77 (new): The method of claim 76, wherein the mouse is a BAFF Tg mouse.

78 (new): The method of claim 74, wherein the salivary gland of the mammal is infiltrated by MZ-like B cells.

79 (new): The method of claim 74, wherein BAFF-R is human.

80 (new): The method of claim 79, wherein the soluble BAFF-R comprises a portion of SEQ ID NO:27 that binds to BAFF.

81 (new): The method of claim 74, wherein BAFF-R is murine.

82 (new): The method of claim 81, wherein the soluble BAFF-R comprises a portion of SEQ ID NO:28 that binds to BAFF.

83 (new): The method of claim 74, wherein the soluble BAFF-R comprises an immunoglobulin Fc domain.

84 (new): The method of claim 83, wherein the immunoglobulin Fc domain is a human immunoglobulin Fc domain.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com